Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S Bénard

Prm34 - French Efficiency Opinions of the Economic and Public Health Committee (Ceesp): Is There an Impact on the Market Access for Innovative Drugs?

Value in Health

English

Related publications

Stock Market Efficiency and Economic Efficiency: Is There a Connection?

English

Prm112 - Incorporation of Anti-Cancer Drugs Adverse Events in Health Economic Opinions of the French National Authority for Health (Has)

English

Is There Information Leakage Around Business Combinations on the French Market?

SSRN Electronic Journal

2002

English

Economic Impact of the End of the Market Exclusivity for Orphan Drugs

English

Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs

English

Pcn355 - Utility in French Health-Economic Opinions: Key Learnings of a Retrospective Analysis in Oncology Drugs

English

Pmu59 - Are There Any Implicit Guidelines for Including Adverse Events in Cost-Effectiveness Models Intended for French Health Authorities? An Analysis of Efficiency Opinions

English

Impact of the Healthcare Payment System on Patient Access to Oral Anticancer Drugs: An Illustration From the French and United States Contexts

BMC Health Services Research

Health Policy

2014

English

Pcn291 - Market Access for Onco-Hematology Medicines : Value of Single Arm Studies - Analysis of French Hta Opinions

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S Bénard

Prm34 - French Efficiency Opinions of the Economic and Public Health Committee (Ceesp): Is There an Impact on the Market Access for Innovative Drugs?

Related publications

Stock Market Efficiency and Economic Efficiency: Is There a Connection?

Prm112 - Incorporation of Anti-Cancer Drugs Adverse Events in Health Economic Opinions of the French National Authority for Health (Has)

Is There Information Leakage Around Business Combinations on the French Market?

Economic Impact of the End of the Market Exclusivity for Orphan Drugs

Was It Worth Introducing Health Economic Evaluation of Innovative Drugs in the French Regulatory Setting? The Case of New Hepatitis C Drugs

Pcn355 - Utility in French Health-Economic Opinions: Key Learnings of a Retrospective Analysis in Oncology Drugs

Pmu59 - Are There Any Implicit Guidelines for Including Adverse Events in Cost-Effectiveness Models Intended for French Health Authorities? An Analysis of Efficiency Opinions

Impact of the Healthcare Payment System on Patient Access to Oral Anticancer Drugs: An Illustration From the French and United States Contexts

Pcn291 - Market Access for Onco-Hematology Medicines : Value of Single Arm Studies - Analysis of French Hta Opinions